Marker Therapeutics Inc. (WKN: A2N7XT) MRKR

Marker Therapeutics, Inc. is an immuno-oncology company, which engages in the development of technologies for the treatment of cancer, including metastasis, and infectious diseases.

It also involves in developing vaccines for breast, colorectal, ovarian, and non-small cell lung cancer.

https://de.marketscreener.com/...?type_recherche=rapide&mots=mrkr

https://markertherapeutics.com/investors/

https://markertherapeutics.com/wp-content/uploads/...X-Transcript.pdf  

http://app.quotemedia.com/data/...he+company&dateFiled=2019-03-15

https://seekingalpha.com/article/...ons-yet-little-recognition-street  

https://www.marketwatch.com/story/...-a-nobel-prize-winner-2019-10-24  

Zahlen für Q3/19

• keine Umsätze
  
• Verlust 5,5 Mio. $
  
• Cash 48 Mio. $
  
• MK 136 Mio. $
  

https://www.markertherapeutics.com/2019/11/...-and-financial-results/

 

6 Patienten in einer Vorprüfungsphase, um die Sicherheit und Äquivalenz eines neuen Reagens zu belegen, wie es in den weiteren Stufen der Studie benutzt werden soll.  

Bin heute morgen mal eingestiegen...

Normalerweise bevorzuge ich Investments im Unternehmen mit kurz bevorstehenden Catalysts aber MRKR ist so ausgebombt, dass mit der gestrigen News zumindest mal eine deutliche Erholungsrally anstehen könnte.

Toi, toi, toi....  

https://www.analystratings.com/articles/...-marker-therapeutics-mrkr/  

Deal mit Aspire Capital über den Kauf von 30 Mio. $ in Stammaktien

https://www.markertherapeutics.com/2020/03/...t-for-up-to-30-million/

 

• MK 102 Mio. $
  
• neues 52 WT
  

 

Zahlen für FY19

• Umsatz 0,2 Mio. $
  
• Verlust 21 Mio. $
  
• Cash 44 Mio. $
  
• MK 74 Mio. $
  

"The Company believes that the financial flexibility provided by the Aspire transaction will enable the cash runway to extend beyond the second quarter of 2021."

https://www.markertherapeutics.com/2020/03/...-and-financial-results/

 

FDA erteilt "Orphan Drug Designation" für MT-401

https://www.markertherapeutics.com/2020/04/...acute-myeloid-leukemia/

https://www.benzinga.com/general/biotech/17/01/...ug-designation-mean

 

Zahlen für Q1/20

• kein Umsatz
  
• Verlust 6 Mio. $
  
• Cash 40 Mio. $
  
• MK 113 Mio. $
  

"The Company believes that its existing cash and cash equivalents will fund its operating expenses and capital expenditure requirements into the second quarter of 2021."

https://www.markertherapeutics.com/2020/05/...-and-financial-results/

 

 

MK 96 Mio. $  

Zahlen für Q2/20

• Umsatz 0,5 Mio. $
  
• Verlust 6 Mio. $
  
• Cash 32 Mio. $
  
• MK 88 Mio. $
  

"The Company believes that its existing cash and cash equivalents will fund its operating expenses and capital expenditure requirements into Q2 2021."

https://www.markertherapeutics.com/2020/08/...-and-financial-results/

 

MK 69 Mio. $
Jetzt steh ich hier schon seit fast einem Jahr an der Seitenlinie und bin mir immer noch unschlüssig ob ich hier investiere oder nicht. Weiter Watchlist.  

HOUSTON, Jan. 5, 2021 /PRNewswire/ -- Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that the U.S. Food and Drug Administration (FDA) lifted the partial clinical hold on the Company's Phase 2 trial investigating the safety and efficacy of MT-401, Marker's lead multi-tumor-associated antigen (MultiTAA)-specific T cell product candidate for the treatment of post-transplant acute myeloid leukemia (AML).  

"We are pleased to move forward with our Phase 2 AML trial of MT-401,...
https://www.prnewswire.com/news-releases/...ical-trial-301200600.html
 

Schön das die FDA die "teilweise klinische Einstellung der Phase-2-Studie MT-401" aufgehoben hat.  Laut dem letzten Q3/20 Bericht soll das Cash bis Q1/22 reichen.

"Cash Position and Guidance: At September 30, 2020, Marker had cash and cash equivalents of $27.0 million. The Company raised $2.2 million through the previously executed $30 million common stock purchase agreement with Aspire Capital Fund, LLC. The remaining $27.8 million available to Marker from Aspire Capital along with current cash available, funds operations into Q1 2022."

https://www.markertherapeutics.com/2021/01/...e-2-aml-clinical-trial/

https://www.markertherapeutics.com/2020/11/...-and-financial-results/

 

https://www.ariva.de/news/...tics-announces-completion-of-new-9049318
Marker Therapeutics Announces Completion of New Manufacturing Facility to Support Clinical Development of MultiTAA-Specific T Cell Therapy Product Candidates..